Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Botulinum Neurotoxin Countermeasure Discovery

by Global Biodefense Staff
October 2, 2014
Botulinum toxin

U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) is contracting with the Institute of Advanced Sciences, Inc. (IAS) in support of the Defense Threat and Reduction Agency (DTRA) Multicenter Program for Developing Treatments for Botulinum Neurotoxin Intoxication (BoNT).

The proposed BoNT Program has two main components:

  • Discovery and development of Light Chain (LC) protease inhibitors
  • Discovery and development of regenerative strategies for accelerating recovery from muscle paralysis

IAS will support this research effort by performing high throughput screening (HTS) of natural product and small molecule libraries. In addition, they will perform whole animal toxicity and protections studies in mice. The estimated value of this action $276,000.

BoNT is a Health and Human Services (HHS) Tier 1 threat agent capable of causing mass casualties and widespread disruption of infrastructure. Exposure to BoNT leads to a symmetrical descending flaccid paralysis of skeletal muscle and impairment of autonomic function. Paralysis can lead to impairment of diaphragmatic function and death.

The only treatment currently available is infusion of antitoxin. The available treatments are generally considered to be inadequate in a bioterrorist or biowarfare situation creating an unusual and compelling urgency for a post-exposure therapeutic.

DTRA has established the BoNT Program that requires multicenter collaboration, with only a few research entities able to conduct specific portions of the program. IAS has been identified as one of three non-governmental collaborators with the available expertise and experience to contribute to the botulinum drug discovery effort immediately, by performing HTS of natural product and small molecule libraries.

Additionally, compounds meeting the minimum criteria for efficacy will be tested for activity in various assays. If initial evaluation of natural product or small molecule libraries fails to yield a candidate compound that is able to protect animals against challenge by BoNT, analogs will be synthesized of the most promising candidates and subjected to a new round of testing.

Tags: AntitoxinsAwardsBotulinum NeurotoxinDefense Threat Reduction AgencyUSAMRICD

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC